Web information on Lenalidomide
Relevant Clinical Literature
Please read pharmacological data limitations
Wikipedia on Lenalidomide (Less technical, ? quality control)
- Multiple myeloma
- Note: EU license for anaemia caused by myelodysplastic syndromes associated with deletion of 5q, refused June 2008. Was approved in Switzerland in November 2011 for anaemia caused by low-or intermediate-1-risk myelodysplastic syndromes.
Cautions and Interactions
- Risk of VTE
- Associated with increased incidence of secondary cancer
A tumour necrosis factor alpha (TNF-α) inhibitor.
- ↑ Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England journal of medicine. 2007 Nov 22; 357(21):2123-32.(Link to article – subscription may be required.)